IL-6 contributes to an immune tolerance checkpoint in post germinal center B cells

Journal of Autoimmunity

Volumn 38, Issue 1, 2012, Pages 1-9

  Yan, Yi ^a   Wang, Ying Hua ^a,b   Diamond, Betty ^a  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b HARVARD UNIVERSITY   (United States)

Author keywords

B cell tolerance; IL 6; Receptor editing

Indexed keywords

B LYMPHOCYTE RECEPTOR; DNA ANTIBODY; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 7 RECEPTOR; RAG1 PROTEIN; RAG2 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA DAMAGE CHECKPOINT; FEMALE; GENE EXPRESSION; GERMINAL CENTER; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; SOMATIC HYPERMUTATION;

ANIMALS; ANTIBODIES, ANTINUCLEAR; ANTIBODIES, BLOCKING; B-LYMPHOCYTES; DNA-BINDING PROTEINS; ESTROGENS; FEMALE; GENE EXPRESSION; GERMINAL CENTER; HETEROZYGOTE; HOMEODOMAIN PROTEINS; IMMUNE TOLERANCE; IMMUNIZATION; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-6; MALE; MICE; MICE, 129 STRAIN; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; OLIGOPEPTIDES; RECEPTORS, INTERLEUKIN-7; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84856631980     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2011.09.004     Document Type: Article

References (50)

1. Wardemann H., Yurasov S., Schaefer A., Young J.W., Meffre E., Nussenzweig M.C. Predominant autoantibody production by early human B cell precursors. Science 2003, 301:1374-1377.
2. Basten A., Silveira P.A. B-cell tolerance: mechanisms and implications. Curr Opin Immunol 2010, 22:566-574.
3. Yarkoni Y., Getahun A., Cambier J.C. Molecular underpinning of B-cell anergy. Immunol Rev 2010, 237:249-263.
4. Gay D., Saunders T., Camper S., Weigert M. Receptor editing: an approach by autoreactive B cells to escape tolerance. JExp Med 1993, 177:999-1008.
5. Tiegs S.L., Russell D.M., Nemazee D. Receptor editing in self-reactive bone marrow B cells. JExp Med 1993, 177:1009-1020.
6. Halverson R., Torres R.M., Pelanda R. Receptor editing is the main mechanism of B cell tolerance toward membrane antigens. Nat Immunol 2004, 5:645-650.
7. Shlomchik M.J. Sites and stages of autoreactive B cell activation and regulation. Immunity 2008, 28:18-28.
8. Vinuesa C.G., Sanz I., Cook M.C. Dysregulation of germinal centres in autoimmune disease. Nat Rev Immunol 2009, 9:845-857.
9. Kuo P., Alban A., Gebhard D., Diamond B. Overexpression of bcl-2 alters usage of mutational hot spots in germinal center B cells. Mol Immunol 1997, 34:1011-1018.
10. Diamond B., Scharff M.D. Somatic mutation of the T15 heavy chain gives rise to an antibody with autoantibody specificity. Proc Natl Acad Sci USA 1984, 81:5841-5844.
11. Putterman C., Limpanasithikul W., Edelman M., Diamond B. The double edged sword of the immune response: mutational analysis of a murine anti-pneumococcal, anti-DNA antibody. JClin Invest 1996, 97:2251-2259.
12. Putterman C., Diamond B. Immunization with a peptide surrogate for double-stranded DNA (dsDNA) induces autoantibody production and renal immunoglobulin deposition. JExp Med 1998, 188:29-38.
13. Tiller T., Tsuiji M., Yurasov S., Velinzon K., Nussenzweig M.C., Wardemann H. Autoreactivity in human IgG+ memory B cells. Immunity 2007, 26:205-213.
14. Rice J.S., Newman J., Wang C., Michael D.J., Diamond B. Receptor editing in peripheral B cell tolerance. Proc Natl Acad Sci USA 2005, 102:1608-1613.
15. DeGiorgio L.A., Konstantinov K.N., Lee S.C., Hardin J.A., Volpe B.T., Diamond B. Asubset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat Med 2001, 7:1189-1193.
16. Wang C., Khalil M., Ravetch J., Diamond B. The naive B cell repertoire predisposes to antigen-induced systemic lupus erythematosus. JImmunol 2003, 170:4826-4832.
17. Wang Y.H., Diamond B. Bcell receptor revision diminishes the autoreactive B cell response after antigen activation in mice. JClin Invest 2008, 118:2896-2907.
18. Hillion S., Dueymes M., Youinou P., Jamin C. IL-6 contributes to the expression of RAGs in human mature B cells. JImmunol 2007, 179:6790-6798.
19. Hillion S., Garaud S., Devauchelle V., Bordron A., Berthou C., Youinou P., et al. Interleukin-6 is responsible for aberrant B-cell receptor-mediated regulation of RAG expression in systemic lupus erythematosus. Immunology 2007, 122:371-380.
20. Kitamura D., Roes J., Kuhn R., Rajewsky K. AB cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin mu chain gene. Nature 1991, 350:423-426.
21. Newman J., Rice J.S., Wang C., Harris S.L., Diamond B. Identification of an antigen-specific B cell population. JImmunol Methods 2003, 272:177-187.
22. Bynoe M.S., Grimaldi C.M., Diamond B. Estrogen up-regulates Bcl-2 and blocks tolerance induction of naive B cells. Proc Natl Acad Sci USA 2000, 97:2703-2708.
23. Grimaldi C.M., Cleary J., Dagtas A.S., Moussai D., Diamond B. Estrogen alters thresholds for B cell apoptosis and activation. JClin Invest 2002, 109:1625-1633.
24. Medina K.L., Strasser A., Kincade P.W. Estrogen influences the differentiation, proliferation, and survival of early B-lineage precursors. Blood 2000, 95:2059-2067.
25. Neurath M.F., Finotto S. IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer. Cytokine Growth Factor Rev 2011, 22:83-89.
26. Hirano T., Yasukawa K., Harada H., Taga T., Watanabe Y., Matsuda T., et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 1986, 324:73-76.
27. Weidle U.H., Klostermann S., Eggle D., Kruger A. Interleukin 6/interleukin 6 receptor interaction and its role as a therapeutic target for treatment of cachexia and cancer. Cancer Genomics Proteomics 2010, 7:287-302.
28. Kishimoto T. IL-6: from laboratory to bedside. Clin Rev Allergy Immunol 2005, 28:177-186.
29. Kopf M., Ramsay A., Brombacher F., Baumann H., Freer G., Galanos C., et al. Pleiotropic defects of IL-6-deficient mice including early hematopoiesis, T and B cell function, and acute phase responses. Ann N Y Acad Sci 1995, 762:308-318.
30. Fattori E., Della Rocca C., Costa P., Giorgio M., Dente B., Pozzi L., et al. Development of progressive kidney damage and myeloma kidney in interleukin-6 transgenic mice. Blood 1994, 83:2570-2579.
31. Espeli M., Rossi B., Mancini S.J., Roche P., Gauthier L., Schiff C. Initiation of pre-B cell receptor signaling: common and distinctive features in human and mouse. Semin Immunol 2006, 18:56-66.
32. Johnson K., Hashimshony T., Sawai C.M., Pongubala J.M., Skok J.A., Aifantis I., et al. Regulation of immunoglobulin light-chain recombination by the transcription factor IRF-4 and the attenuation of interleukin-7 signaling. Immunity 2008, 28:335-345.
33. Wei C., Lai L., Goldschneider I. Pre-pro-B cell growth-stimulating factor (PPBSF) upregulates IL-7Ralpha chain expression and enables pro-B cells to respond to monomeric IL-7. JInterferon Cytokine Res 2002, 22:823-832.
34. Milne C.D., Fleming H.E., Paige C.J. IL-7 does not prevent pro-B/pre-B cell maturation to the immature/sIgM(+) stage. Eur J Immunol 2004, 34:2647-2655.
35. Kishimoto T. IL-6: from its discovery to clinical applications. Int Immunol 2010, 22:347-352.
36. Nagafuchi H., Suzuki N., Mizushima Y., Sakane T. Constitutive expression of IL-6 receptors and their role in the excessive B cell function in patients with systemic lupus erythematosus. JImmunol 1993, 151:6525-6534.
37. Chihara N., Aranami T., Sato W., Miyazaki Y., Miyake S., Okamoto T., et al. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci USA 2011, 108:3701-3706.
38. Mihara M., Takagi N., Takeda Y., Ohsugi Y. IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 mice. Clin Exp Immunol 1998, 112:397-402.
39. Tsantikos E., Oracki S.A., Quilici C., Anderson G.P., Tarlinton D.M., Hibbs M.L. Autoimmune disease in Lyn-deficient mice is dependent on an inflammatory environment established by IL-6. JImmunol 2010, 184:1348-1360.
40. Hillion S., Rochas C., Youinou P., Jamin C. Signaling pathways regulating RAG expression in B lymphocytes. Autoimmun Rev 2009, 8:599-604.
41. Kotzin B.L. Systemic lupus erythematosus. Cell 1996, 85:303-306.
42. Walker S.E. Estrogen and autoimmune disease. Clin Rev Allergy Immunol 2010, 40:60-65.
43. Roubinian J.R., Talal N., Greenspan J.S., Goodman J.R., Siiteri P.K. Effect of castration and sex hormone treatment on survival, anti-nucleic acid antibodies, and glomerulonephritis in NZB/NZW F1 mice. JExp Med 1978, 147:1568-1583.
44. Carlsten H., Tarkowski A., Holmdahl R., Nilsson L.A. Oestrogen is a potent disease accelerator in SLE-prone MRL lpr/lpr mice. Clin Exp Immunol 1990, 80:467-473.
45. Stein B., Yang M.X. Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-kappa B and C/EBP beta. Mol Cell Biol 1995, 15:4971-4979.
46. Galien R., Garcia T. Estrogen receptor impairs interleukin-6 expression by preventing protein binding on the NF-kappaB site. Nucleic Acids Res 1997, 25:2424-2429.
47. Tagoh H., Kishi H., Okumura A., Kitagawa T., Nagata T., Mori K., et al. Induction of recombination activating gene expression in a human lymphoid progenitor cell line: requirement of two separate signals from stromal cells and cytokines. Blood 1996, 88:4463-4473.
48. Rochas C., Hillion S., Saraux A., Mageed R.A., Youinou P., Jamin C., et al. Transmembrane BAFF from rheumatoid synoviocytes requires interleukin-6 to induce the expression of recombination-activating gene in B lymphocytes. Arthritis Rheum 2009, 60:1261-1271.
49. Llorente L., Zou W., Levy Y., Richaud-Patin Y., Wijdenes J., Alcocer-Varela J., et al. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. JExp Med 1995, 181:839-844.
50. Bouaziz J.D., Yanaba K., Tedder T.F. Regulatory B cells as inhibitors of immune responses and inflammation. Immunol Rev 2008, 224:201-214.